Skip to main content
Delfa

← All trials/NCT06982378

OMICS in MASLD

Not yet recruiting

GLP-1 RA on Liver OMICS in MASLD

Effect of Glucagon-like Peptide -1 Receptor Agonist on Liver Tissue and Plasma Lipids in MASLD

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

-

Estimated enrollment

30

Study population

MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes

Eligibility highlights

-

Primary endpoint

•Changes in lipidomics profile on use of GLP-1 RA

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06982378
Org study IDPRO00050604

Timeline

Milestones

Study first posted2025-05-21actual
Last update posted2026-03-10actual
Study start2026-07estimated (month precision)
Primary completion2028-12estimated (month precision)
Study completion2028-12estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

MASH / NAFLD / liver fibrosisObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

known diagnosis of MASLD by histology, also have diabetes/ obesity

Inclusion criteria

•known diagnosis of MASLD by histology, also have diabetes/ obesity
•on treatment with GLP-1 RA at stable dose

Exclusion criteria

•unable to have a liver biopsy, recent change in medication for diabetes or hyperlipidemia
•on immunosuppression, liver or kidney transplant
•pregnancy

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Changes in lipidomics profile on use of GLP-1 RA

Time frame:1 year

descriptive

Secondary/protocol endpoint/low confidence

Changes in associated proteomics and transcriptomics with the use of GLP-1 RA

Time frame:1 year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.